Investment report on BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. (Pink Sheets:BIEL). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

BIEL's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, BIEL is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

BioElectronics Corp. (BIEL) designs, develops and markets a variety of drug-free, anti-inflammatory patches for a range of medical indications. The Company's patch products, which are marketed under the name ActiPatch Therapy, deliver pulsed electromagnetic field therapy, an anti-inflammatory and pain relief therapy. The ActiPatch Therapy products combine a miniaturized microchip, power source and antenna in a soft, flexible outer envelope. When applied to the body, these devices deliver a pulsed radio frequency signal into the body on a 27 megahertz (MHz) frequency wave that induces a low frequency electromagnetic field to damaged cell tissue.

Message Board Search for BIEL: http://www.boardcentral.com/boards/BIEL

In the report, the analyst notes:

"BIEL, on April 1, 2010, announced the completion of its full year audit and the filing of Form 10K with the Securities and Exchange Commission. BIEL is now a fully reporting company however has not reported since the financial statement for the period ending September 30, 2009.

"BIEL announced today that its Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain, and for reducing the use of pain medication associated with menstruation, while ActiPatch™ is now approved by the South Korea Food and Drug Administration (KFDA) for reduction of muscle pain."

To read the entire report visit: http://www.microstockprofit.com/lp/BIEL